These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39139778)

  • 61. Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.
    Andraka-Christou B; Saloner B; Gordon AJ; Totaram R; Randall-Kosich O; Golan M; Stein BD
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):492-503. PubMed ID: 35772010
    [No Abstract]   [Full Text] [Related]  

  • 62. Expanding Access to Medications for Opioid Use Disorder: Program and Policy Approaches from Outside the Veterans Health Administration.
    Priest KC; McCarty D; Lovejoy TI
    J Gen Intern Med; 2020 Dec; 35(Suppl 3):886-890. PubMed ID: 33145685
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Total cost of care associated with opioid use disorder treatment.
    Toseef MU; Durfee J; Podewils LJ; Blum J; McEwen D; Hanratty R; Everhart R
    Prev Med; 2023 Jan; 166():107345. PubMed ID: 36370891
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The development of a recovery coaching training curriculum to facilitate linkage to and increase retention on medications for opioid use disorder.
    Moffitt T; Fallin-Bennett A; Fanucchi L; Walsh SL; Cook C; Oller D; Ross A; Gallivan M; Lauckner J; Byard J; Wheeler-Crum P; Lofwall MR
    Front Public Health; 2024; 12():1334850. PubMed ID: 38425462
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial.
    Hser YI; Ober AJ; Dopp AR; Lin C; Osterhage KP; Clingan SE; Mooney LJ; Curtis ME; Marsch LA; McLeman B; Hichborn E; Lester LS; Baldwin LM; Liu Y; Jacobs P; Saxon AJ
    Addict Sci Clin Pract; 2021 Apr; 16(1):24. PubMed ID: 33879260
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
    Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
    Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
    Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
    Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Latine perspectives on the impact of family, perceptions of medication, health systems, incarceration, and housing on accessing opioid agonist therapy: A thematic analysis.
    Ascunce Gonzalez K; Swartz N; Linares MA; Gelpí-Acosta C; Chatterjee A
    J Subst Use Addict Treat; 2024 Aug; 167():209491. PubMed ID: 39179210
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Trends in Use of Medication to Treat Opioid Use Disorder During the COVID-19 Pandemic in 10 State Medicaid Programs.
    Austin AE; Tang L; Kim JY; Allen L; Barnes AJ; Chang CH; Clark S; Cole ES; Durrance CP; Donohue JM; Gordon AJ; Huskamp HA; McDuffie MJ; Mehrotra A; Mohamoud S; Talbert J; Ahrens KA; Applegate M; Hammerslag LR; Lanier P; Tossone K; Zivin K; Burns ME
    JAMA Health Forum; 2023 Jun; 4(6):e231422. PubMed ID: 37327009
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adolescent-Serving Addiction Treatment Facilities in the United States and the Availability of Medications for Opioid Use Disorder.
    Alinsky RH; Hadland SE; Matson PA; Cerda M; Saloner B
    J Adolesc Health; 2020 Oct; 67(4):542-549. PubMed ID: 32336560
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
    Shastry S; Nobel I; Allen LR; Richardson LD; Vidal K; Manini AF
    Am J Emerg Med; 2022 Jan; 51():114-118. PubMed ID: 34735968
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.
    Stopka TJ; Rottapel RE; Ferguson WJ; Pivovarova E; Toro-Mejias LD; Friedmann PD; Evans EA
    Int J Drug Policy; 2022 Dec; 110():103803. PubMed ID: 35965159
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Post-incarceration outcomes of a comprehensive statewide correctional MOUD program: a retrospective cohort study.
    Martin RA; Alexander-Scott N; Berk J; Carpenter RW; Kang A; Hoadley A; Kaplowitz E; Hurley L; Rich JD; Clarke JG
    Lancet Reg Health Am; 2023 Feb; 18():100419. PubMed ID: 36844014
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions.
    Thomas CP; Stewart MT; Ledingham E; Adams RS; Panas L; Reif S
    JAMA Netw Open; 2023 Mar; 6(3):e232052. PubMed ID: 36884250
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
    Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
    J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tailoring dissemination strategies to increase evidence-informed policymaking for opioid use disorder treatment: study protocol.
    Crable EL; Grogan CM; Purtle J; Roesch SC; Aarons GA
    Implement Sci Commun; 2023 Feb; 4(1):16. PubMed ID: 36797794
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.
    Hollander MAG; Chang CH; Douaihy AB; Hulsey E; Donohue JM
    Drug Alcohol Depend; 2021 Oct; 227():108927. PubMed ID: 34358766
    [TBL] [Abstract][Full Text] [Related]  

  • 79. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
    Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
    Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
    [No Abstract]   [Full Text] [Related]  

  • 80. Availability of Medication for Opioid Use Disorder Among Accountable Care Organizations: Evidence From a National Survey.
    Newton H; Miller-Rosales C; Crawford M; Cai A; Brunette M; Meara E
    Psychiatr Serv; 2024 Feb; 75(2):182-185. PubMed ID: 37614155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.